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CHAPTER I. INTRODUCTORY BACKGROUND 
75
se-selenomethton1ne and 75se-selenocystine were the first effective 
:;amma-emitting label beari.nJ aml.no acids analo::;s produced. Radioiodinated 
tyros '.ne was 1')roduced more than 10 years earlier, hut was not usable for 
most studies, as tts label :i.s extremely cleavable in biological systems. 
. 75 Since its synthesis in 1960, the biological properties of Se-
selenor.rethioni.ne were extensively studied in animals. It has been 
clinically used for localization studies (scanning) of the pancreas, 
parathyroid and malignant lymph nodes. But little, if any, informat:ton 
was available on its fate tn the human body. As a radioactive agent, the 
radiation dose delivered to the patient from a diagnostic procedure is of 
concern. One of the most important factors in calculati.ng this dose is 
the :i:tologi.cal half life of the compound. This factor in humans was 
estimated to 'lE! between 15 and 144 days. In addition, the radiation dose 
to various organs was calculated on the hasi.s of distribution studies in 
animals. 
The purpose of the present study, was the determi.nation of the 
biological half lHe of 75se-selenomethionine in man. As there were 
reports of different localization patterns of the drug in healthy subjects, 
in patients with pancreatic diseases and in patients with malignant 
lymphomas, these three categories of subjects were chosen for the present 
studies. In addition, tissue di~tri~ution of 75se-selenomethionine was 
to be determined in man by in vivo counting and radioactive assay of 
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has been used l-1ithout noticeable decrease in the grovth rate of the 
yeast. After inoculation with 50 mg of pressed yeast, grot.,th was 
carried out in 3-l Fernbach flasks containing 500 ml of media. Vigorous 
agitation provides aeration and the temperature was maintained at appro-
ximately 30°. Grovth and subsequent chemical manipulation were carried 
out in fume hood to prevent inhalation of volatile selenium compounds. 
7 
The yeast was harvested by centrifugation after 18-24 h. Inoculation 
of 75se-selenomethionine into cells proceeds to approximately 50% and then 
stops. ThiE yield can be increased by adding glucose to the media after 
the first harvest readjustment to pH 5 and allowing gr01;1th to proceed for 
another 24 h. An additional 25% yield ~as obtained. 
The yeast was dehydrated with ethanol and refluxed 3· min. with ligroin 
to remove lipid materia 1. After washing with ethyl ether the yeast HaE; 
air dried. To remove carbohydrates, the dry yeast (l-3g) was extracted 
with 70 ml 5% trichloroacetic acid for 15 min. at 90° and t-;ashed once 
with cold trichloroacetic acid. 7.5·80% of the yeast radioactivity remained 
in the insoluble protein fraction. 100 mg each of L-methionine and L-
cyt~tine were added and the yeast protein i;.;as hydrolyzed 5 h. in boiling 
5 N HCL. Bumping was controlled with glass w-ool. Control of bumping by 
vigorou~ shaking or bubbling with air reduced the yield. Immediately 
after hydrolysis the humin >Jas centrifuged or filtered off and the HCl 
removed by vacuum evaporation to dryness 3-5 times. The reF>idue was taken 
up in 200 ml water. The pH at this point must be over 1. 5. This solution 
containr, 50-60% of the original yeast radioactivity. 
The selenium amino acids were separated by ion~exchange chromatography 
-on Dowex-50-X8 resin. 200·400 mei.:;h resin. cleared of fines by repeated 
decantation, was prepared in a column l in. in diameter and 5 in. long. 
The resin was pretreated on the column v1ith 4N HCL and then washed until 
the pH of the effluent is over 2. 
8 
The protein hydrolysate was passed through the column at 2·3 ml/min 
follo•;ed by 150-200 ml of 1'1as11 water. 95-98% of the radioactivity remains 
on the column. 75se-selenomethionine was eluted with 1.1 N HCL passed 
through the column at the rate of 1.5-2.0 ml/min. Radioactivity in the 
effluent t.?as followed by counting one-di-op samples taken every 10 ml. 
75se-f;eleuometh1onine appeared in the eluate between 300-500 ml, resembling 
quite closely the elution of (35s) methionine from this resin. 
The yield by this method was about 25% of the initial radioactivity. 
!::.2.::l· Distrihution 1 fate and excretion. Thirty minutes following 
an intravenous injection of 75se-selenomethionine, the blood level drops to 
2(1% of its two minute level. Then it gradually rises up to 75% at 4 hours 
when it reaches plateau and slowly declines to 60% at 24 hours (11). 
Penner showe<l that practically all the 75se-selenomethionine activity 
reappearing in the blood is incorporated in serum proteins (12). In his 
experiment the peak and plateau were reached at 5 hours, and accounted 
for 25% of the administered dose. 
Awad found the maximum protein bound activity at 8 hours, accounting 
for 22% of the administered dose (13). He also showed that the biological 
halt life of the plasma proteins "'as 17 days, the main fraction being in 
albumin (half life 8 days). Penner found that the incorporation into 
-erythrocytes b considerably less than in plasma, and that at least 85'%. 
75 of the RBC Se•selenom.ethionine was incorporated in hemoglobin (14). 
75 Awad confirmed this result, but studying the aspect of RBC Se-seleno-
9 
methionine activity more extensively reported that the maximum concentra· 
tion in RBC occurs at 35 days (5'7.. of injected dose), when it reaches a 
plateau up to 100 days, then a decline starts reaching minimal levels 
at 1~5 days (13). He suggested that this pattern follows very much the 
life span of the erythrocyte. He accounted for 95?. of the 75se-seleno• 
methionine in the RBC as being incorporated in hemoglobin. 
These results were recently confirmed (15). 
75 Many laboratories studied the tiRsue distribution of Se-seleno• 
methionine in various species, at varioufl tiwrn following an intravenous 
injection. 
Blau and Manske reported the relative specific activity in dogs. 
2 hours after the injection to be (10): 
Pancreas : Liver : Spleen : Kidney : Blood = 30 : 6 : 1 : 5 : 1.5 
Zuidema and Kirsh (16) found in the monkey, that 2 hours after injec-
tion a ratio of: 
Pancreas : Liver : Kidney • 3.5 : 2.5 : 1 
Anguileri and Marques found 8 hours and 7 days after injection the 
following ratios in the mou~e (17): 
8 hours : Pancreas : Liver : Kidney : Testis • 4.5 : 1.7 : 4.2 : l 
7 days : Pancreas : Liver : Kidney : Testis = 0.6 : 0.7 : 1.1 : 1 
-10 
They found over a period of 7 days that i:hile the pancreas activity 
disappears fast, the testicular and skeletal muscle activity increase 
slowly, and a slow di&appearance in all other organs. Awad and co-
workers compared the distribution in rats at 30 minutes and 24 hours after 
the administration (18): 
30 minutes : Pancreas : Liver : Kidney : Muscle = 15 : 6 : 6 : l 
24 hours : Pancreas Liver : Kidney : Muscle • S : 4 : 6 : 1 
They found that while at 30 minutes between 60% and 771. of the 75se-seleno-
methionine was incorporated in proteins in the various tissues investigated, 
at 24 hours more than 95% was incorporated. 
Sternberg and Imbach studied the distribution of 75se-selenomethionine 
on the subcellular level in the rat liver cells and found 60 minutes after 
the injection (19): 
Micro~;omes 17.81. 
Mitochondria 11.8% 
Nucleus lJ.9% 
Supernatant 50.4% 
TCA precipitate 9.1% 
75 Awad and co-workers reported that after degradation of Se-seleno-
methionine, 75se may reappear in the precursor amino acid pool of the liver 
i ~ f L 75s 1 ' d L 75 l i n rorms o - e-se enocyst1ne an - Se-se enocyste ne. 
75
se-selenomethionine is excreted in the urine (15,21,22) t>ile (15) 
and by expiration (19). The rate of excretion varies widely from species 
to species. It has been reported that 80% was excreted in 12 weeks in dogs, 
-11 
"while in monkeys the excretion is considerably slower" (15). In mice it 
·JaS found to be 7 days (17). In rats 15-20 days (23). Attempts have been 
75 
made by various investigators to e$timate biological half life of Se-
selenomethionine in man on the basis of animal data. The results vary 
from 15-20 days (23,24), to 23 days (21,26,27,28), to 100 days (22,24,25) 
and up to 144 days (30). A~cording to these figures, the respective 
investigators have calculated the whole body irradiation delivered by a 
tracer dose of 250 pci 75se-selenomethionine anY'-rhere between 0.6 rads (23) 
to 2.:~ rads (30). 
I-h-'.\. 75 Amino acid properties of Se-selenomethionine. The bio lo;~ica l 
behaviour of 75se-selenomethionine has been compared to that of 35s-methio-
nine and natural occurring L-methionine. Its incorporation into proteins 
7·-
and the fate of :>Se-e:elenomethionine containing proteins have been compared 
'1 < 
to ~~S-methionine analogue compounds (31-37). 
75 Spencer and Blau (31) ~tudied the intestinal transport of Se-seleno-
rnethionine in the hamster. By administering ~imultaneously the 75se-seleno-
methionine and 35s analogues, they found identical transport across the 
everted hamster inter.tine sacs in the presence of carrier methionine. 
They found the km for both ami.no acids to be 0 .8 X 10-jM» suggesting the 
compound to be a good indicator for amino acid absorption studies. Hansson 
and Blau (32) reported identical rate and amount of incorporation of 75se-
selenomethionine and natural L-methionine in pancreatic juice in the cat. 

lJ 
1-c. Medical applica~i<?_~s of 75se-nelenomethionine. 
I-c-1. Pancreatic scanning. The use of 75se-selenomethionine for 
the scannin,5 of the pancreas was first suggested by Blau and Manski (10) 
from data obtained on dogH. In 1962 Blau and Bender reported the first 
successful pancreatic scans in man (29). Her ever, the close anatomic 
relationship of the pancreas and the liver presented a serious problem. 
Although the 75se-selenomethionine concentration in liver tissue is less 
than in the pancreas (1 :5), the total activity in the liver is much greater 
due to itB more than 20 fold larger mass. Therefore, the visualhation of 
the pancreas was obstructed in most by strong (-emission from the adjacent 
liver (10,21-30,40-53). Thus, various methods have been suggested to 
improve the visualization of the pancreas. Sodee suggested the blocking 
of the estimated liver area with heavy lead shields (26 ,28). Rodriguez-
Antunez suggested the administration of ~ grain morphine 30 minutes before 
75 
the Se-selenomethionine to induce constriction of the sphincter of Oddi, 
slowing the secretion of pancreatic juice and allo\•ing for a higher build-
up of radioactivity in the pancreas (43,44). Tabern claimed to improve the 
1 li i f ' . d i i i h 7 5 1 , i . v sue zat on o tne pancreas ')Y a m n ster ng t e Se-se enometn oni.ne 
15 minute~ after an intravenous infusion of an amino acid mixture for enzyme 
synthesis which was continued throughout the scanning procedure (50). Other 
methods requirec.1 the overnight fasting of the patient, 2 glasses of milk for 
breakfast, 3 hours later 1 unit per kg body veight pancreozymin, to empty 
the pancreas and stimulate fresh enz.yme synthesis. After another hour the 
75 
Se-selenomethionine was given I.V., plus 15 mg oral Probanthine to inhibit 
,, I 
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Figure 4. Pancreatic scan - lead shield (26) 
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Figure_!!. Parathyroid scan (55) 
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x:·. 
Figure l!J. LyMp 01ona seen (f.;'.) 
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variou.c' intensity levels were printed in different colors. So for a 
pre-:-;et count rate of J.,10%, the colors of the prlntin; ribbon will change 
in 12.5% increments. (For example; r!-12.5% white, 12.5-25% black, 25-
J7.5% purple, etc.). 
The ar.>0ve described factors are the main ingredients of the modern 
rectilinear scanner. Since the description of Cassen's model in 1951, 
many improvement.s have been introduced in scanning techniques. Uhile the 
Ul 
ori;_;ina l , canner was designed for thyroid scanning ~dth I, today more 
than i:;, organs can 1)e visua liz.ed by scanning utilizing a pharmacy of over 
5') radiopharmaceutica ls. These techniques and drugs have recently been 
discussed in tv:o major internationa 1 sympoda in Greece and Oak Ridge 
(7J,74). 
I-d-2. Whole body counting. The first '-·'hole :Jody counting r.:as per-
formed witli an ionization chamber by Schlundt and co-workers in 1929 • to 
de cermine the radium and mesothorium levels in man (75). Due to the low 
sensitivtty of such a system, whole hody counting ·"'as not \·:ictely used till 
the early 50 's • '-hen Reines and co-,:orkers described the liquid r>cintilla-
tion '.hole body counter (76). In 1955, Marinelli introduced the Na! (Tl) 
crystal ·,:hole :lody counting method (77). The advantage of this method 
over the liqui<: ficintillation method is about 3 times as sensitive as the 
solid crystal. The most commonly used geometrical counting configuration 
is the "tilted cl1air method."--describetl iirst by Miller (78). The cali-
oration problems associated "tdth the operation of a whole body counter 
t,ave :>een descriued and discm~seu at t:he Vienna Whole Body Counting 
symposium, 1%2 (79,80,81). Th~ major aspects are: matching of the 
phototube:~, background index, resolution, stability, efficiency and 
cro:.!»-over. 
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for radioactivity. Sign::U'.icant activity above ;,ackgrounc: was cause for 
re.iection. 
Th(~ interior !;urfaces were covered :)y 1/8 11 lead sheet. A standard 
tilting ctiair '.as useci ior positionin,; of the patient. 
27 
The detector '"as mounted upon an extension arm with rotational 
coupling allowing ;;ide angle orientation of the cylindrica 1 axis of t11e 
crystal. The extension arm moves laterally on a box girder, the l>ox girder 
longitudinally on a rail permitting three dimensional positioning of the 
cry~;tal. Calii1ration in the X, Y and Z axis is measured by built-in metal 
measurin& tapes. The extension arm is motor operated. 
The patient may be observed on two external TV monitors via a TV 
camera with wide angle lens vithin the room. Communication with the patient 
is carried on i)y tvo-way intercom. A small TV set with outside antenna 
couplin,~ is mounted on the crane for patient entertainment (fig. 11). 
Fresh air •;1as supplied at a rate of 23. 9 cubic feet per minute through 
the shielded room when operating with closed doors. 
The 4 11 X 8" Na! (Tl) crystal contains 3300 ml of detecting volume. 
It is enclosed in an unshielded stainless steel container. The crystal 
is equipped '!.Jith three matched RCA photomultiplier tubes having calcite 
£.1ces to reduce 41)K background leve 1. This output is f:ecl into a preamp 
circuit and then into a 512 channel pulFe height analyzer equipped with IBM 
input-output typewriter, Mosely X-Y Recorder and tally tape output and input 
(fi.';;. 12). The analyzer has a channel summation and processin,5 section. 
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Fi5ure 11 . View of intei-ior of the shielded room through the open doors 
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222 
Background variability related to Rn level 
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Variation of background index (B) with position 
of detector in counting room. (Average of 8 one 
hundred minute counts) 
Position 11 (cpm/cc) 
Center .3030 
s - E corner .2878 
s - w corner .2969 
N - w corner .2919 
N - E corner .2989 
TABLE I 
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Figure ll•. Gamm.a spect-.~·1.m of :,ackground countr 
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end of the rods. The vari.ous rods were nu>nd throughout the room, and 
countf! were taken at each position. A profile of the isorespon&e surfaces 
is sho..,,;n in fig. 15. The symmetry and shape appear satisfactory. 
Further calibration was accomplished with a Nuclear Enterprii:;e 70 kg 
phantom filled with 70 liters distilled water. The average background 
index with this phantom \,:as 0.246 cpm/cc (fig. 16). The sensitivity, 
131I, 37Cs and 40K background, resolution and isotope interference for 
were measured by uniform distribution of the various isotopes in the phantom. 
All measurements were performed at a 10 kev/channe 1 calibration. The results 
are summarized in Table II. 
13111 37Cs 60 "Point" sources (O.l cc) of and Co were introduced into 
the center of the various parts of. the phantom and the point source geometry 
factors for these isotopes established (Ta~le III). The crystal was posi-
tioned at a 50 cm distance from the designated center of the phantom. Using 
the single chair technique, the geometry factors vary significantly at the 
extremities and the head, and this variation is less when counting higher 
energy gamma ~missions. 
To characterize whole body counters, a figure oi' merit must be derived. 
To derive this figure the measurable factors are the sensitivity and the 
background count for specific isotopes. The efficiency figure for any 
isotope may be derived by squaring the sensitivity and dividing by the 
background count. The overall efficiency of the system may be defined as 
the geometric average of the isotopes used. The three isotopes observed 
cover the spectral range of interest in ,,hole body counting. The figure 
35 
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Figure 15. Isoresponr.e cross-section plot of NaI (Tl) crystal 
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Figure 16 . Phantom man in counting position 
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Geometric factors 131 37 for I, Cs, 60co point sources at 
various locations in phantom. 
Isotope 
1311 37cs 60Co 
Location 
Head 0.17 0.27 0.31 
Neck o. 77 1.04 1.00 
Chest 1.00 1.00 1.00 
Pelvis 0.64 0.84 0.70 
Thigh 1.07 1.39 1.13 
Shin 0.32 0.64 0.48 
Arm 1.42 2.20 1.90 
TA~LL III 
of merit (M) is then defined as the overall efficiency divided oy the 
integral background over this "pe.ctral range. 
(M) is t>pecifically defined as follows: 
M = ---"'--
B 
where .-n is the overall isotope efficiency: 
'-
rr7! is the efficiency of individual isotopes in ? 
their respective energy bands 
1) 
s 1 is sensitivity of cpm per ~1Ci 
bi is background 
39 
where B is the background index the integral background 
in counts per minute per cc of crystal. The integral 
band measured was 0 .1 to 2 Mev. 
U-c. Development of the multi-energy isotope scanner. 
One of the objects of this gtudy ·was to observe in vivo distribution 
of 75se-selenomethionine in man by means of rectilinear scanning. As 
11entioned in the introduction, one of the limiting factors for this pro-
cedure 1.-1as the relatively hi;~h concentration of 75se-selenomethionine in 
the liver, making it extremely difficult to observe other organs in the 
l) 
In case of 4°K, cpm per g. potassium 
40 
abdominal and thoracic region. Therefore, a commercially available scanner 
(Picker Magnascanner V) was converted to be able to subtract radiation of 
different energies rrom different organs and display them in different 
colors. Ultimately a tape recording cathode ray display system was 
adapted for improved color image presentation. 
II-c·l. The block diagram. The hlock diagram of the system is illus-
trated in fig. 17. The following parts are added to the conventional 
scanner: input mixing box, a dual channel analyzer, an output mixing box, 
two dua 1 ra teroeters, a DC-frequency converter and a DC-isolator. An 
additional pulse amplifier was wired into the scanner ratemeter chassis 
(EXT.PLS.-AMP on fig. 17), to permit independent recording on the photo and 
print systems. The modes of operation of the modified scanner are selected 
by turning a single o•deck rotary switch, "•hich is also shown in fig. 17. 
Fig. 18 is a photograph of the modified scanner. An additional modifica-
tion is the introduction of a "one-way circuit 11 to the mechanism of the 
scanner. This circuit permits the scanner to record vhi le moving in one 
direction only, returning over the same line at 200 cm/min speed. Since 
scalloping results from a de lay in print-out of alternate scan lines due to 
the factor of time constant, this type of scanning eliminates scalloping com-
pletely, thus making high-speed, sloi1 time constant scanning possible. The 
relatively slow time constant (1 sec) is necessary for subtract scanning 
to permit sufficient time for the subtraction event. 
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SCANNER SECTION[ POSITION I - NORMAL SCANNER OPERATION 
POSITION 2- SUBTRACT 
POSITION 
·- z 
COLOR 
I POSITION 4- SUBTRACT + 2 COLOR 
I POSITION ~- 2 COLOR, SUBTRACT ON FILM POSITION 6- 2 COLOR, !nl ISOTOPE ON FILM 
I IDITAILID P'UNCTION CCSCltll"TIClll IW TlXTI 
l:XT•MP. 
'" . .,.III_ - .,, ..... 121U ·······- ... ,.=n··~~,,rR~· .... : .. ·· :···· ~.2!.ll 1 a 1 4 COLOR~, 4 a 4 1 1 4 1 - 6-DECK FUNTION SWITCH !.C, ' 1 I I I l I L O I 0.,~ .-~~~.,,:•on~• 0••• •' 
(MIXlltilllll-Cl..L!i IC-~- Jll EltT. P~AllP .Jll. COl.OltN~ J!l l"KOTO"-i.#'rlt • .B ~ DC. -- DECK NO. 
Block diagram of the modified. scanner and switchini~ arrangement 
for various modes of operation 
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l!&ure 18. Photograph of the modified scanner . ¥i0difications on right 
IJ.:-c..:~-.-~. Logic and pl:ocec~ure. 
In this ponition the scanner 1ill function a'; a con-
ventional color i:~canner, only the original component~ of the scanner being 
included in the circuit. 
Pulses of different ener~;ies from two isotopes are 
discriminated by two pulse height ana ly~:ers, ie<l to i.ndividual components 
of a dual ratemeter, subtracted one from the second, and fed throu;jh a DC 
to a frequency converter (fig. 19), to the -,z. V input of the scanner rate-
meter. The difference of the pulses may be recorded on ooth the photo and 
mechanica 1 recording devices. The major application of this mode of scanning 
75 
appears to us to be for pancreatic scanning. Se-selenometldonine and 
198 
colloidal Au are administered to the patient aiaultaneoudy. One channel 
deteeta the 411-keV 198 Au ga.a emisaton the other detecte'.I the 270 and ,:BiJ 
keV 75se-aeleDOMthionine &ammo cmi!Jsion, eech tin.'Ou~i:i a iJ.;; keV ·.:indQ'!,:. 
Phantom studies provdd tl\at this uystem is ,;;uit~ c•'iective. 
Figure 20 shous top (a) and later, (b) scanning of a phantom without 
b . d ( ) d (d) · b · h 198A su trac ting, an c an _. are respective scans, su tract1ng t e u 
75 
signals from the Se-selenomethionine signals. Our phantom system consists 
of a Marinelli Beaker filled with 90 µCi 75se-selenomethionine and 90 µCi 
198Au in 900-cm3 fluid, and a 150-cm3 plastic bottle which contained 75 µCi 
75s 1 h" · e-se enomet 1on1ne. This bottle inserted into the hollow part of 
the beaker. Figure 20 shows clearly that the signals from the surrounding 
beaker may be completely eliminated electronically. 
The detector is directed over the maximum 198Au count of the liver. 
44 
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Figure 19. Schematic diagram of the DC-f'requency converter 
Figure 20 . 
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0. b 
• 
c d 
(a) End on scan of 75se activity in two concentric containers,. 
visualizing 75se gallltna photo peak. (b) Scan of 7.5se activity 
in two concentric containers• vb~alizing 75se gamma photo 
peak. Lateral view. (c) nd on scan of 75se activity in two 
concentric containers, outer container neutralized by subtraction 
of 198Au activity from 75se activity. (d) Scan of 7>se activity 
in two concentric containers, outer container neutralized by 
s.ubtraction of 198Au activity from 75se activity. Lateral vie • 
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The patient then receives 250 pCi of 75se-selenomethio11ine intravenously. 
The count rate for 198Au and 75se-selenomethionine are observed simul-
taneously on the individual count•rate meters. Within 10 to 15 min., 
75 
the Se-selenomethionine count stabilizes. The amplitude of deflection 
of the two isotopes are equated, adjusting the respective channel widths, 
and the 198Au count placed in negative mode. Scanning at a speed of 60 cm/ 
min and at 4-Dltl'I line intervals, the scan can be completed in 20 min. 
Figure 21 (a) shows a pancreas scan carried out by the regular method, 
,,ithout Hubtract, and (b) shows the same patient scanned by the subtract 
method. 
to~ . .i.tiQ..n_3.:.. In this position, tv'O isotopes emitting photons of 
different energy level8 may be scanned simultaneously and a color display of 
t~1e distribution of each of the isotopes in a different color obtained. The 
overlying parts will appear on the scan in intermediate shades of the two 
colors. Pulses from the preamplifier are fed into a dual channel analyzer. 
The outputs of the two channels are split, feeding into a dual ratemeter 
and a mixing circuit consisting of two diodes to prevent feedhack from one 
channe 1 to the other. The pulses from the mixing circuit are fed through 
the i'-Canner ratemeter and drive the stylus. The ratemeter outputs are 
subtracted one frorn the other by a :milt-in circuit. The difference, which 
may be po!iitive or negative, used to r.ubtract one isotope from the other may 
no:; db;play the subtracted inotope in one color and the positive in another 
color by driving the scanner's color control through a DC isolator designed 
and constructed in this laboratory. This isolator is essential, as the DC 
output of the subtractor and the DC input of the color drive are isolated. 
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Figure 21. (a) Pancreas scan using 75se-selenomethionine alone. 
(b) Same patient scanned by the subtract method. 
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Schematic diagram of the ''color calibrate 11 circuitry 
The DC if;olator schematic diagram is shmin in tig. Z2. In or:ernticn, the 
DC output of the subtract circuit is connected to a #6977 Amprex light 
~0urce. Any change in the DC output, positive or negative, will alter 
the light intensity of this lamp. The light output is measured by a cadmium 
r,ulfate (eds) cell; the DC output of the eds cell drives the color control. 
Thii' output is proportional to the light output and thu~ proportions 1 to the 
relative output from the tHo ratemeters. 
The standard color tape of the scanner consists of seven usable 
colors, with black at one extreme and dark red at the other; purple, blue, 
green, orange and a light red are intermediate colors. The color tape i1as 
been modified using only two colors-blue and red, and four shades oi each, 
dimi.nishing in darknee!; from the extremes to the center. The range of color 
is controlled by the scanner "color calibrate" potentiometer control and by 
the resistor switch in fig. 22. The center color is set by the potentio-
meter in fig. 22. If only pulses of energy A are detected, the color band 
:<ill he deflected to one extreme and the pulses will be recorded in color A. 
If only pulses of energy B are detected, the color ribbon ~rill be deflected 
in the opposite direction and only color B will be printed. If pulses 
of both energies nre detected, the color ribbon will move between the 
e:.:tremes printing out intermediate shades of the two colors. If A is 
greater than B. the lighter shades of color A will be printed, the darker 
shades indicating the magnitu<le of the difference. If A is less than B. 
shades of color B will be printed. The intensity of the counts is indi· 
cateJ ,;y the density of impubeB printed, which is controlled by the :;um 
of A B. 
Fiaure 2.'.l • 
. 
F,is:ure Z4 . 
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Color &can euergy modulation of the phantom in Fig . 20 . 
Liver and pancreas visualized in separate 
198Au signals in one channel (blue)~ 75se 
in second channel (red) . 
75 
colors: Se + 
signals alone 
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Figure 2:' sho1,.s the energy-color scan of a phantom, consisting of 
198 
5U :•Ci Au in a Marinelli Beaker and 50 f.tCi 75se-selenomethionine in a 
cylindrical container inserted 3/4 into the hollow part of the beaker. 
The 3old is printed out in black, the selenium in red, and tne overlapping 
part in the intermediate colors. Figure 24 is a scan of the liver containing 
75
se-selenomethionine and 198Au shown in blue and the pancreas conta:'.ning 
75se-selenomethionine in red. 
to~i!i2_.n_4~ In this position, both the subtract and the two color 
circuits are activated. The net output of the subtract is fed from the 
DC-frequency converter to one of the two ratemeters of the color control 
cua.l ratemeter an<l to the input of the output mixer box. In this setting 
3cannin:;; two isotopes, one will be displayed in one color and the 11subtract" 
of the t~o in a second color. This factor is particularly useful if, for 
instance 1 the pancreas and the liver are to :>e displayed. Then the 
198Au 
wi 11 be displayed in one color and the extrahepa tic 7 5se-se lenome thionine 
198 
minus Au pulses in the ~econd color (fig. 25). 
By means of this method it was possible for the first time to demon· 
strate that hepatomas may be visualized by scanning as positive lesions 
(fig. 26). 
f_o!?_i!i2_.n_5.:.. It is possible to simultaneously visualize two organs in 
separate color on paper and a subtract scan demonstrating a single organ, 
with tne other subtracted, on film. 
io~i!i£.n_6~ In this mode of operation, two isotopes drive the color 
control and stylus as described in position 3, ;.·hile the pulses of a third 
are fed through the scanner pulse height analyzer, bypassing the stylui;i 
Figur~ 2,5. 
Figure 26 . 
Liver and pancreas: 198Au signals from liver in red• 
75se- 198Au signals from pancreas in blue . 
The first hepatoma ever to bo vi ualized as a positive 
scan (in blue) hy the dual color subtract method . 
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Circuit diagram of "one way-one isotope" scanner modification. 
Figure 28. 
b 
'· I 
. i 
(a) Nol'.'tnal liver and pancreas visualized by scanning 
modification in ig . 27. (b) N. rmal liver and carcinoma 
of the pancreas visualized by s canning modification in 
Fig . 27 . 
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!t can be calculated: 
D =TX S 
where D = displacement in cm 
T = time constant in seconds 
S = scanning speed in cm/second 
(e.g. If T.,. O.l second, S • 1 cm/second, D • 0.1 X 1 = 0.1 cm in each 
direction, which is negligible). 
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The subtract circuit described in position 2 may also be used with 
this method, allowing the "subtract scan" to he visualized in one color 
anrl one of the two isotopes in a second color. A representative scan of 
a liver and pancreas in a normal individual and one with carcinoma of the 
pancreas is seen in fig. 28 a and b. To accomplish the subtract mode, a 
mode si-iftch, a DC to AC converter and a dual ratemeter are added to the 
circuitry (fig. 27). 
The displayed color image was futther improved by the introduction 
of a four-track tape recorder coupled to a CRT display unit into the 
circuit. /1 block diagram of the essential connection of the scanner-
recorder-display ''ystem is shown in fig. 29. A photograph of the sy~;tem in 
fig. 30. A conventional scanner vas used, to \..;hich one additional single 
channel analyzer wafl added. The outputi;; of analyzer one and two are recorded 
on channel 3 and 4 respectively. If a subtraction scan is desired, switch 
S1 is flipped into poi: it ion ~. In this position the information from analyze 
one will be recorded on channel 3 and the "subtract output" (information from 
analyzer two less the information from analyzer one) on channel 4. The x and 
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Block diagram of the scanner-tope recorder-display unit system. 
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Figure 30 . Photograph of the tape recorder -display unit 
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y movements of the scanner are recorded on channelB 1 and 2 respectively, 
The recorded information is played into the readout unit and ~,111 be dis-
played on a white phosphor cathode ray tube (CRT). The x and y deflection 
of the CRT heam are controlled by channels 1 and 2 of the tape. The beam 
intensity (z axis modulation) is proportional to the signal output from 
channels 3 or 4, depending on the position of s2 • The CRT display is 
continuously monitored by a Polaroid camera loaded with a color film. 
A filter holder was built between the CRT screen and the camera, where 
filters of various colors may be mounted. When the information from 
channel 3 is played back filter A is used to obtain a picture of the 
distribution in color A. Then channel 4 is played back, recorded on the 
same film, using filter B. The diEtribution of isotope B .,,ill thus be 
di~played in color B. The overlay areas will appear in a mixture of colors 
A and B, distinct from A or B. The replay is carried out at a speed 16 
times faster than the recording (60" per minute vs. 3.75" per minute). 
The tape used is a standard type 3M-203 tape. The replay procedure may be 
repeated as many times as desired changing the intensity, contrast and 
background cut-off setting~ for each channel. This permits the achieve-
ment of optimal displays as well as detailed analysif of the organs scanned. 
II·d. The subjects studied. 
II-d-1. Total body biological half life. The biological half life 
of 75se·selenomethionine vas determined by t.hole body counting in 3 groupE 
of subjects, a 11 males. 
A- Controls: Nine clinically healthy volunteers from the personnel 
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DIAGNOSES AND PHYSICAL CHARACTERISTICS OF THE SUBJECTS FOR 
TOTAL BODY HALF LIFE EVALUATION 
SUBJECT DIAGNOSIS AGE WEIGHT (kg) HEIGHT (cm) RACE 
B.K. Normal 46 82 178 c 
E.G. Normal 49 111 178 N 
T.K. Normal 45 80 173 c 
E.K. Normal 44 73 173 c 
J.G. Normal 40 95 168 c 
J.S. Normal 41 86 180 c 
E.B. Normal 44 84 178 N 
J.K. Normal 41 77 180 c 
M.B. Normal 47 63 185 c 
E.S. Lymphosarcoma 72 69 180 c 
M.T. Hodgkin's dis. 57 65 180 N 
M.K. Ret. cell sa. 48 68 175 c 
R.R. Lymphosarcoma 57 73 163 c 
M.Z. Hodgkin's dis. 27 77 175 c 
E.F. Chr. pancrtis. 60 93 183 c 
W.E. Chr. pancrtis. 40 70 175 c 
A.R. Chr. pancrtis. 45 65 180 N 
J.D. Pancr. insuff. 47 57 178 c 
& severe diab. 
mellitus 
TABLE IV 
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of the Research Service of the V.A. Hines Hospital. 
B- Malignant Lymphomas: Five patients \.:ith various types of malignant 
lymphomas from the Hema to logy ward, V .A. Hines Hos pita 1. 
c- Pancreatic Diseases: Four patients with non-neoplastic pancreRtic 
diseases from the Gastrointestinal ward, V.A. Hines Hospital. 
Table IV summarizes the physical characteristics and diagnoses of 
the subjects. 
The malignant lymphoma patients did not receive chemotherapy with 
antimetabolites throughout the duration of the study. 
II-d-2. In Vivo and necropsy &tudies. 'I'.-:o hundred and twenty 
patients were scanned for this study. All patients were males ranging 
30-76 years. Seventy were found to be clinically normal subjects. The 
others suffered from various diseases as listed in Table V. One hundred 
and nine of the 220 were evaluated by the dual isotope scanning method 
,·ith mechanical color display, the other 111 by the tape recorder display. 
Three patients were counted for the evaluation of the biological 
75 half life of Se-selenomethionine over various areas of the body. The 
areas are sho~~·n in fig. 31. 
One patient died of hepatoma 52 days follo\e!ing the administration of 
250 uci 75se-selenomethionine. Tissue samples were obtained from the 
pancreas, kidneyA, normal liver tissue and the hepatoma. The tissues 
were weighed and assayed for radioactivity with a scintillation well 
counter. Another patient died of bronchogenic carcinoma 72 hours folloving 
DISTRIBUTION OF PATIENTS BY DIAGNOSIS AND ORGANS SCANNED 
PANCREAS LIVER MYOCARDIUM 
Clinical normal 70 70 10 
Ca of pancreas 20 20 
Pancr. insuff. 39 39 4 
Cirrhosis 34 34 1 
Pancreatitis 16 16 1 
Other GI disorders 36 36 2 
Brain lesions 
Hepatoma 5 5 
TOTAL 220 220 18 
TABLE V 
BRAIN 
2 
1 
3 
6 
6" ,:,. 
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the administration of a similar dose. Tissues from most of this patient's 
0 rgans <Nere assayed for radioactivity. The tissues are li!:.ted in Table VI. 
u-e. Procedures. 
II-e-1. Half life studies. Folloving a shower, a special go,-m was 
assigned to each subject. The gown was previously tested for radioactive 
contamination. This was necessary to assure that radioactivity detected 
while counting the patient was not from extrinsic sources. Next the 
subjects W'ere counted by the whole body counter to determine their 
natural radioactivity and to check whether they contained any traces of 
radioisotopes that might have been previously administered to them for 
other procedures. These counts were conFi<lered as base line readings. 
T•,,,o uci 75se-se lenomethionine were administered intravenoue. ly to the 
subjects. Ten minutes l~ter they t.-ere counted. Each subject was counted 
three times, 5 minutes each, and the sum of the three counts divided hy 15. 
Thia reading was considered as the zero time 100% reading for each indi-
vi dual. 75 A standard test source of Se-selenomethionine was counted 
preceding and follocing the patient in order to check the stability of the 
counting system. This standard reading also served for correction of the 
readings from the subjects for radioactive decay. The subjects were counted 
one hour, 4 hours, one day and then every second or third day for 3 weeks, 
then once a week for the next 6 veeks, then monthly and after 100 to 120 
days, every 100 days approximately, up to one year. 
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Tissue concentrations and dosime~ry 72 hours following 250,..,.ci 75se-selenomethionine. 
(1!£) ORGAN WT.(gm) 100 gm TOTAL % c em C •Ta Q D 
Kidney 3SO 1.80 6. 3 .04S 1.08 41 3. 8S 
Liver 17SO 1.62 28 .4 .041 0. 98 68 s 1n 
Pancreas 80 1,13 0. 9 .028 0.67 25 1 66 
Spleen 100 0. 90 0.9 .023 0. SS 28 1.48 
Gallbladder 20* o. 70 )<. 0.1 .018 0.43 20 o. 92 
Bile 10* 
' 
70 so.1 .018 -- -- --
Adrenal glands 15 0.67 :i;o.1 .017 2.00 15 3. 64 
Thyroid 20 a.so ~ 0.1 .013 1. 56 20 3. 34 
Prostate 25 0.40 ~O.l .010 1.20 23 2. 28 
Intestines & Stomach 1750* 0. 36 6.4 .010 0.17 68 0 02 
Solid Tumor 550 0 .38 2 .1 .010 1.10 47 4 38 
Lung 3300 0.34 11.2 .008S 1 00 lQS 7 q,; 
Metastatic L"mnh Node 30 0.33 :fl 0.1 0083 1 en n ? 41 
Testes 40 0.25 :s 0 .1 .0063 0. 75 24 1.81 
Pericardium 80ir 0 .25 0.2 .0063 0. 7S 25 1. 87 
Myocardium 420 0.24 1.0 .0060 0. 72 44 2. 77 
Brain 1360 0 .22 3.0 .DOSS 0 .66 6S 3. 64 
Blood 5000* 0.22 11.0 .0055 -- -- --
Urinary Bladder 150 0.20 0. 3 .0050 0.12 31 0. 35 
Diaphragm 200* 0.15 0.3 .0038 0.46 34 1.43 
Aorta 100* 0 .13 t5 0.1 .0033 0.40 28 1.07 
Skin 6100* 0.09 s. 5 .0022 0. 27 40 0. 95 
Skeletal Muscle 30 ,ODO* 0.06 18 .o .0015 0. 20 58 0.95 
Bone 7000* 0.04 2. 8 .0010 0.12 40 0.42 
*Estimated weight 
TABLE VI 
II-e-2. Scanning procedures. 
He!hQ.d_o~e~ The patient is prepared by fasting overnight. Break-
fast consists of 300 grams of gelatin dessert containing 4.5 grams of 
protein which is fed because of its relatively low methionine content. 
In the presence of abundant other amino acids, selenomethionine concen-
tration in the pancreas may be enhanced. Thirty minutes following this 
198 
meal, the patient is administered 100 µci of Au colloid by intra-
venous injection. Seventy-five minutes after breakfast, the patient 
received 1/6 to 1/4 grains of morphine sulfate, the dose depending upon 
the patient's weight and tolerance, to assure constriction of the 
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sphincter of Oddi (43). Fifteen mg of propanthelin bromide (Probanthine) 
were administered at this time to decrease the fluid volume of the 
pancreatic secretion (95). The two agents used simultaneously should 
prevent phenomena related to increased intraluminal pressure in the 
pancreatic ducts (96), without altering selenomethionine accumulation. 
Me!_l'l2.d_t~-o..!. The patient received a regular breakfast folloved in 
198 30 minutes by 100 µci of Au colloid by intravenoua injection. 
Common to the two methods, 90 minutes to 120 minutes after breakfast, 
the patient is placed supine with the detector over the right lobe of 
the liver. Two hundred and fifty microcuries of 75se-selenomethionine 
are administered intravenously. The count rate for 198Au and 75se-seleno-
methionine are observed simultaneously. 75 Within 10 to 15 minutes the Se-
selenomethionine count stabilizes. The amplitude of deflection of the two 
ratemeters is equated by a balancing circuit or by window width adjustment. 
198 The Au is subtracted. The patient is scanned at a speed of 60 cm per 
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circuits were utilized. The scanning technique was described in II-c-2. 
scans extended from the nipple line to the iliac crest. Thirty-six 
patients were free of known pancreatic or hepatic disease, 16 had 
unconfirmed diagnosis by the criteria described below, 10 had carcinoma 
of the pancreas, 19 had chronic pancreatitis with exocrine insufficiency, 
and 17 had Laennec's cirrhosis. Finally, eight of the nine patients 
listed in Table VII as ''Other Diagnoses" were cases of recurrent pancrea-
titis, and the ninth had a massive intraperitoneal hepatoma following 
splenectomy. carcinof88 of the pancreas was proven by subsequent laparo-
tomy or necropsy. Chronic pancreatitis was evaluated by a positive secre-
tin·pancreozymin test, x-ray demonstration of pancreatic calcification, 
glucose tolerance determination, and steatorrhea as determined by the 72-
hour stool fat. The diagnosis of cirrhosis was based upon clinical findings 
and confirmatory liver biopsy. Many of the cirrhotic patients had histories 
of alcohol ingestion, but none had laboratory or clinical evidence of 
pancreatic disease. 
The factors evaluated were anatomical configuration of the liver 
and pancreas and also of the spleen when present in the scan. This 
included the presence or absence of diffuse or focal defects in the liver 
and pancreas. The relative level of 75se-selenomethionine not cleared by 
the liver or pancreas and visualized outside of this organs was also 
estimated. The specific criteria for determination of norm.al pancreas, 
carcinoma of the pancreas, chronic pancreatitis and cirrhosis are des• 
cribed in Chapter III (Results). The problems of distinguishing between 
the various diagnoses are included in Chapter IV (Discussion). 
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EFFICACY OF DIAGNOSIS OF PANCREATIC DISEASE BY DUAL CHANNEL SCANNING 
DIAGNOSIS FROM SCAN 
CONFIRMED DIAGNOSIS INSUFFI-
NO. NORMAL CA CIENCY CIRRHOSIS 
Clinical Normal 36 31 0 4 1 
Carcinoma of Pancreas 10 2 §. 0 0 
Pancreatic Insufficiency 19 6 0 12 0 
Cirrhosis 17 4 3 0 10 
Other Diagnosis 
Acute recurrent pancreatitis 8 4 0 4 0 
Postoperative splenectomy 
with massive intraperi-
toneal hematoma 1 0 1 0 0 
Diagnosis Unconfirmed 18 
TOTAL 109 
TABU: VII 
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The other 86 pancreas scans were performed by the tape recording 
method described in II-c-2. The criteria for diagnosis remained unchanged, 
but its accuracy appeared to be improved, due to the superior quality of 
the images obtained and the possibility to ttrescan 11 the "patient" from the 
tape, changing the contrast and intensity settings of each channel, for 
optimal visualization. 
All the myocardium scans were performed on patients referred for 
pancreatic scans. No special preparation was needed. The scanning was 
started immediately following the completion of the pancreas scan. 
For brain scans, the normal subjects were from the same group of 
patients. After the pancreatic scan was completed, they received a dose 
of 5 mci 99nl.rc-pertechnetate, and ten minutes later the brain scanning 
started. The distribution of each isotope was displayed in a different 
color. 
Both, the myocardial and brain scans were carried out by the tape 
recording technique. 
II-e-3. Directional counting. The three patients on whom the 
biological half life in various areas of the body was determined were 
counted by the "directional method". A 2" Na! (Tl) crystal with a flat 
field collimator composed the detector system. The counting system was 
a RIDL- 0- -spectrometry modular system. 75 The patient received 50 µci Se-
selenomethionine intravenously and counts were registered for 90 seconds 
over each area. The patients were counted 15 minutes following the injec-
tion, one hour, 4 hours and then on days 1,2,3,6,7,8,9,10,13,14,21, and 28. 
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Figure Jl. 75 Se-selenomethionine elimination curves over various body areas 
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In an attempt to quantify &he result~ tl~ counts verc co0pared to 
that from a one liter plastic flask containing 50 µci 75se-selenomethionine 
diluted in one liter ~ater. 
72 
CHAPTER III. RESULTS 
III-a. The biological half life of 75se-selenomethionine. 
III-a-1. Total body. The counts-corrected for decay and nor-
malized as l.00 for time Eero--vere plotted on individual graphs. The 
zero time count was 24.000 cpm ranging bet"'1een 21,000 and 26,000. The 
ordinate was the logarithm of the normali~ed counts, the abscissa--the 
time. In 7 out of 9 control subjects the graph resolved into three clear 
segments. The general expression of the .function is of the type: 
-~1t -~2t p -~Jt y • P1e J P2e l le 
The curves of the three patients ·with chronic pancreatitis resolved 
in an identical pattern. The patient with severe pancreatic insufficiency 
with high grade diabetes mellitus showed an extremely fast disappearance 
of 75se•selenomethionine from the body. 
The curves from all five lymphoma patients resolved only into two 
segments. the general function being of the type: 
.>-1t .>-2t 
y • P1e P2e 
Figures 32a 1 32b 1 32c and 32d show a typical curve of a normal 
subject, a patient with chronic pancreatitis, a malignant lymphoma and the 
patient with pancreatic in.sufficiency and diabetes mellitus, respectively. 
As there was no significant difference between the controls and the 
pancreatitis subjects, and only one patient with pancreatic insufficiency 
associated with diabetes mellitus was counted, the subsequent statistical 
analyses were performed on normal controls and lymphoma patients only. 
The curve for each subject was fitted by the least square method, 
using a DAC-512 computer. Each segment was fitted for a general expression 
!!J~ure 32. 75 
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of the type: 
lnP • - >-. t 
where P represents the fraction of the administered dose that will be 
excreted from the body at a rate. ~ is referred to as the excretion 
constant. t- is the time• in days, the units of/.. are (days)·1• P has 
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no units. The values of P and~ for each segment in each group were aver-
aged and according to these calculated data, the average curves plotted. 
The average values corresponding to the various times (t) at which counts 
were performed were introduced into the respective graphs. P and ~values 
of the averages were calculated and found to be identical to the averages 
of the individual P and /..values. 
From the~ values. the corresponding half life (Tj) for each seg-
ment may be calculated by the following equation: 
T~ • ln2 • 0,6931 
>- f.. 
The three segments of the control graphs were designated A, B and C 
correspondingly. The respective Pt and T; values: PA,1\ A• TA; PB,/\ B• 
TB and Pc,f- C• Tc. In the lymphoma patient graphs. segment B was con• 
sistently absent. 
As mentioned above, the corresponding P- values indicate the fraction 
of the administered dose that is excreted at the rate 1\ • In other words 
the fraction P1 of the administered dose will hove in the body a biological 
half life r1 • Thus, the overall biological half life (Tb) of the total 
dose administered will equal the sum of the products P1T1: 
Pc • l.00 
t 0·4 
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Figure 33. 75se-selenomethionine elimination curves in normal 
controls and lymphomas (average values). 
T 
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TOTAL BODY ELIMINATION CONSTANTS 
TA** PA TB PB TC Pc Tb Te 
Controls 
J.K. 24.0 0.12 0 0 48 0.88 45 33 
M.B. 12.0 0.11 0 0 84 0.78 67 44 
E.B. 6.0 0.09 8.0 0.12 92 o. 72 72 46 
J.S. 4.0 0.175 6.5 0.125 85 0.68 59 40 
J.G. 4.0 0.09 6.0 0.12 73 o. 77 57 40 
E.K. 4.0 0.13 8.0 0.14 123 0.67 84 50 
T.K. 4.0 0.125 7.0 0.105 90 o. 76 70 46 
B.K. 4.0 0.11 18.0 0.11 123 o. 77 97 55 
E.G. 24.0 0.165 23.0 0.105 102 o. 72 76 48 
Average 9.5 0.12 8.5 0.09 91 o. 76 73 46 
S.D. 8.0 0.03 8.0 0.05 36 0.07 21 10 
Lymphoma 
E.S. 0 0 0 0 42 1.00 42 31 
M.K. 4.0 0.06 0 0 46 0.94 43 32 
M.T. 12.0 0.07 0 0 58 0.93 54 37 
M.Z. 24.0 0 .17 0 0 50 0.86 43 32 
H.R. 12 .o 0.13 0 0 50 0.90 45 33 
Average 10.5 0.08 0 0 49 0.93 45 33 
S.D. 9.0 0.03 0 0 6 0.06 8 5 
Chr. Pane. 
E.F. 9.0 0.07 8.5 0.11 98 0.82 81 48 
W.E. 11.0 0.05 10.0 0.09 76 0.86 66 43 
A.R. 10.0 0.06 8.0 0.08 69 0.86 60 40 
Average 10.0 0.06 9.0 0.09 81 0.85 69 44 
J.D.*) 12.0 0.20 0 0 26 0.80 21 18 
*) Pancreatic insufficiency & severe diabetes mellitus. 
**) TA - in hours; all other T's - in days. 
TABI.E VIII 
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BIOLOGICAL HALF-LIVES AND DOSE DISAPPEARANCE (AVERAGE VALUES ± S.D.) 
-1 
TA (hr) PA TB(days) PB Tc(days) Pc (days) Tb(days) Te(days) 
Controls 9.5 ± 8 0.12 ± 0.03 8.5 ±8 0.09 ± 0.05 91 ± 36 o. 79 ± 0.07 0.0076 ± 0.003 73 ± 21 66 ± 10 
Lymphomas 10.5 ± 9 0.08 ± 0.03 Absent 49 ± 6 o. 93 ± 0.06 0.0140 ± 0.003 45 ±8 33 ±5 
Significant 
differences 
(P values*) < 0.01 < 0.01 < 0.01 < 0.05 < 0.05 
TABLE IX 
The effective half life (T ) is a function of both the physica 1 
e 
half life (Tp) and the biological half life: 
l 1 1 
--- -Te Tp + T0 
75 for Se-selenomethionine, Tp = 120 days, therefore: 
120 Tb 
Te • T -~ 120 (Te and Tb in days) b 
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Table VIII sho'l,1S the individua 1 data, Table IX summarizes the significant 
results. 
The difference between the corresponding averages of the control 
data (Xe) and lymphoma data (X1) • .. ,ere analyzed for significance by the 
t- test: 
The corresponding p values are shown in Table IX. 
Figure 33 sho\<:s the half life curves of the average values of controls 
and lymphomas. 
The results of this experiment may be summarized as follows: 
1) The biological half life curve of 75se-selenomethionine in normal 
control subjects is resolvable into 3 distinct phases, rapid, inter-
mediate and slow, each being characterized by a different excretion 
rate. 
2) In subjects suffering from malignant lymphomas, the intermediate phase 
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is absent. 
3) the slow phase is significantly faster in lymphomas, compared to 
controls. 
4) Both, the overall biological half life and the effective half life 
is significantly shorter in lymphoma patients compared to controls. 
5) There appears to be no significant difference regarding the rapid 
phase. 
6) There appears to be no significant difference bet~een the half life 
curve of patients with chronic pancreatitis compared to controls. 
7) In a single case of severe pancreatic insufficiency associated with 
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severe diabetes mellitus, the elimination rate of Se-selenomethionine 
from the body is abnormally fast. 
111-a-2. Half life and tissue distribution in various organs. The 
biological half life in various parts of the body was measured by the 
technique described in II-e-3. A typical set of curves is shoim in fig. 
31. The units on the ordinate represents percent per solid angle volume 
of the detector system. As this technique of counting ~as rather crude. 
no attempt was made to actually quantify these data. They are hovever 
of qualitative value, as they represent correct half lifes and concentra-
tions in the parts counted, relative to each other. 
The organs counted by this method were the liver (l)*• spleen (2)*, 
heart (3)*, intestines (4)*, urinary bladder (5)* and skeletal tUUscle in 
the right and left thighs (6,7)*. 
*-these numbers refer to those in fig. 31. 
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It appears that among the 7 sites counted, the highest concentration 
of 75se-selenomethionine is in the liver. The concentrations in the spleen, 
heart and intestines are similar. A somewhat lower concentration over the 
urinary bladder. The skeletal muscle concentration is lower by a factor 
of about 5. The biological half lifes in the liver, heart, spleen and 
urinary bladder are similar, about 30 days. In the intestines it is 
shorter, 17 days. In skeletal muscle, however, there appears to be a 
very slow release of incorporated 75se-selenomethionine, unmeasurable over 
the period observed. A half life of infinity was assumed for this tissue. 
The concentration of 75se-selenomethionine in the organs of the 
patient ~ho died of bronchogenic carcinoma (II-d•2) was determined. 
Tissue samples from the organs listed in Table VI t.iere obtained. Where 
possible the entire organ was wei3hed. The weight of the organs marked 
by *) are estimated. Tbe concentrations in some organs of the patient who 
died of hepatoma are listed in Table x. In the first patient (Table IV). the 
highest concentration was found to be in the kidney. the lo~est in bone. 
The highest total percent of the administered dose was found to be in 
the liver, the lowest--0.11. or less--in many organs, mostly of small mass 
of less than 50 gms. 
The data obtained from the lung, are atypical. as the lungs were 
fibrous and necrotic with large infiltrations of tumor mass. This accounts 
for the heavy weight and high percentage dose in this organ. 
75 Se concentration in different organs 52 days following 250 ,.lilC 
75se-methionine administration. (Single case, hepatoma.) 
Organ 
Liver tumor 
Liver 
Liver 
Kidneys 
Spleen 
Pancreas 
75Se 
Concentration 
7 .2 X 10-3 JJ.C/gJ 
8.1 x lo-3,....c/g 
8.2 X 10-3,MC/g 
10.2 X 10-3Jl.(C/g 
5.5 X 10-3,.cAC/g 
1.9 X 10-3.i4{C/g 
TABLE X 
Organ 
Weight 
2400 g } 
255 g 
600 g 
80 g 
% Administered 
Dose in Organ 
7.7 
1.0 
1. 3 
< 0.1 
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Pancreatic scan b~ gold subtract method, showing progressive 
accumulation of 7 Se activity at (a) 30 minutes (b) 2 hours 
30 minutes (c) 4 hours 30 minutes, and (d) 6 hours 40 minutes 
fo llo-v·ing injection of 7 5se-se lenome thionine. The subject 
was a 49 year old male with normal pancreatic function. 
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198 Au in t~e liver ct 
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Figure 37. ~) p;1otoscan showing distribution of 75se-se lenomethionine 
in the liver and pancreas of the subject in Fig. 36. Note 
overlap of the t<"O organs. (b) Subtract photoscan of the 
same subject showing the pancreas without liver interference. 
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Figure 38. Subtr;>ct photoscan of patient with subsequent surgically 
proven carcinoma of the pancreas. 
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Fisure 39. A selenomethionine photoscan using gold subtract method of the 
pancreas of a 42 year old male patient with chronic pancreatitis. 
This pancreas was shrunken in size; its length was 10 cm as 
compared to 15 to 20 cm length seen in normal subjects. 
89 
tiave been completed oy this mEthod to mHke any significant evaluation of 
this technique in pancreatic pathology. Two illustrative scans are 
sho',m to indicate the findings in pancreatic disease. Figure 38 shows 
the pancreatic scan in carcinoma of the pancreas. The day following the 
scan, laparotomy demonstrated that this patient with obstructive jaundice 
had virtual destruction of the head of the pancreas and a portion of the 
tail by carcinoma. Figure 39 indicates a scan obtained in a patient with 
a history of chronic pancreatitis. The pancreas was visualized, but was 
markedly shrunken in size. Decreased size was not necessarily an observed 
characteristic in other patients with this diagnosis. 
III-b-2. Pancreas and. liver energy-to-color modulation: M:ichanical 
display. The correlation of diagnostic results in the D9 patients studied 
by this method is summarized in Table VII. 
Patients without pancreatic diseases. The pancreas and liver ~ere 
consistently visualized in 30 of 36 subjects free of pancreatic and hepatic 
disease and no significant defect "'88 seE:n. Principal anatomic variations 
encountered by thif' method were similar to the above described. These 
variations in configuration have been described previously by other 
authors (25). Selenium activity exclusive of hepatic and pancreatic ~as 
minimum, and was principally confined to the myocardium (see be lo~·). The 
spleen t.1as not visualized (fig. 28a). 
Carcinoma of the pancreas. The pancreatic scan Qf 8 of 10 patients 
~v'ith carcinoma showed "cold" areas in the gland. The spleen was not 
visualized, and there was little 75se-selenomethionine outside of the 
ancreas and the liver areas. In one atient with carcinoma of the bod 
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and tail of the pancreas, these areas were devoid of 75se-selenomethionine 
out the head appeared norma 1. In many instances the "cold" areas were 
diffused, and later anatomical examination revealed replacement of the 
pancreas in these areas hy masses of tumor tissue. In three instances 
the diagnosis of carcinoma was made in patients in whom barium meal 
examinations were interpreted as normal by a qualified radiologist. The 
relative merit of barium meal versus scanning was not accomplished. In 
one instance the two-color print out revealed cold areas in the liver and 
pancreas, without 198Au in the spleen or 75se-selenomethionlne i.n the 
abdominal field exclusive of the liver and pancreas, which made possible 
a correct diagnosis of carcinoma of the pancreas with metastases to the 
liver. In two other cases, scans were interpreted as normal in patients 
with suggestive x-ray evidence for carcinoma; laparotomy confirmed that 
the pancreas was normal. Fig. 28b exemplifies a dual color scan of 
pancreatic carcinoma. 
Chronic pancreatitis. In 12 of 19 patients with chronic pancreatitis 
the scan also differed greatly .from those of normal subjects. These 
patients did not have evidence of liver disease, and splenic uptake of 
19F 
'Au •ms absent in every instance, with normal deposition of radiogold 
throughout the liver. 75se-selenomethionine activity did not delineate 
the pnncreas because of excessive 75se-selenomethionine activity in the 
body exclusive of the liver and pancreas. It has subsequently been deter• 
mined (by the tape recording method) that the pancreas is discernible in 
thet;e cases if much ~_;reater background erasure is used. This pattern has 
not been observed in norm.al subjects, patients with cirrhosis without chronic 
PICKER COLORSCAN 
Figure 40. Pancreatic insufficiency visualized by the method 
described in Fig . 27 . 
Piaur;e 'f-1. Cirrhosis of the liver visua lized by the method 
described in Fig . 21 . 
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F1sµre 42 . Liver-pancreas scan by the tape method. Both organs are 
normal with no overlap . 
Figure 43 . Normal liver and pancreas, with overlap. White area 
represents area of overlap. 
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figure 44 . No~l liver and pancreas . (a) No background subtraction. 
(b) 30% $Ubtraction, (c) 50% subtraction, (d) 70% subtraction. 
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c 
d 
Figure 44 . Normal liver and pancreas. (a ) No bac1 ground subtraction, 
(b) 30% subtraction , (c) 50'7. subtraction , (d) 70'7.. subtraction . 
Background manipulation has been useful in demonstrating cold 
lesions in the liver which may not be apparent because of saturation 
effects at low background subtraction levels. Display of the tape 
recorded scan at any desired level of background subtraction for either 
channel of information is readily accomplished without destruction of 
any of the information in question. Massive replacement of the liver 
by metastatic malignancy may occur with no significant localization of 
75se·selenomethionine within the lesions. The pancreas is clearly 
visualized despite virtually complete overlay of the deformed liver. 
198 The enlarged spleen is visualized in red by accumulation of Au in 
figure 45. 
The positive visualization of a hepatoma in the right lobe of the 
liver proven at laparotomy demonstrates massive accumulation of 75se-
selenornethionine (fig. 46). The pancreas was apparently not able to 
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compete with the lesion for the amino acid analogue and is not visualized. 
A small spleen is seen adjacent to the superior aspect of the left lobe. 
Using subtraction of gold from selenium activity as previously descrihed, 
results in separate color visualization of the tumor even if the concen• 
tration of 75se-selenomethionine in the liver and tumor are equal. 
Pancreatic defects are well visuali~ed as exemplified by the focal 
decrease in 75se-selenomethionine concentration in an individual with 
verified carcinoma of the pancreas (fig. 47). The focal lesions are quite 
apparent when compared with scans of the normal pancreas (fig. 42). 
Clinical evaluation of this set of results has as yet not been per-
formed. 
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Figure 45. Meta ta tic involvement of the liver . Despite complete 
overlap of the liver and pancreas , each organ is clearly 
v!sua lited and delineated by this method . 
Figure 46 . Repatoma visualized by the tape recording method. 
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Figure 47. Carcinoma of the pancreas. 
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III-b-4. Hepatoma. Five patients suffering from hepatoma were 
scanned. In three of these patients the hepatoma was visualized by a 
"positive 11 selenium lesion. 
A conventional colloid 198Au scan of the liver sho'V'S a "cold" mass in 
the liver, ~.ilich may be produced by any space occupying lesion, malignant 
or benign (fig. 48). The dual color scan, ho~:>ever, shows a ''hot" concen-
tration of sclenomethionine in the lesion (fig. 49). This was found to 
be typical of hepatoma. 
Fifty-t•,;o days after these scans were performed, a necropsy revealed 
a hepatoma. A massive tumor was found in the liver (fig. 50) precisely 
at the location revealed by the scan. Tumor cells were spread throughout 
the entire liver vith several nodules of various sizes. Five gram speci-
mens of various organs were obtained and the 75se-selenomethionine concen-
tra tion was determined (Table X) and revealed to be equal in both liver and 
hepatoma at 42 days post administration. No information is available con-
cerning relative concentration at the time of scanning. Assuming equal con-
75 
centration at the time of scanning, the Se-selenomethionine in the hepatoma 
198 
:.:ould still be visualized by this method as Au did not concentrate in the 
tumor allowing the nonsubtracted 75se-selenomethionine in the hepatoma to 
be visualized as a separate color. Figure 46 is an example of a hepatoma 
scan produced by the tape recorder method. 
III-b-5. Brain scanning with 75se•selenomethionine and 99mTechnetium. 
The concentration of 75se-selenomethionine in the brain follov>ing a 250 µci 
dose of this isotope for pancreatic scanning is sufficient to visualize the 
Figure 48 . 
Figure 49 . 
Fiaure 50. 
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Conventional 198Au liver photoscan, revealing "cold" spot, 
indicative of a s pace occupying lesion. 
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Two•color subtract scan of same patient showing concentration 
o .E 75se in "cold" spot (figure identical to #26) . 
The patient's liver at necropsy, revealing a large hepatoma 
at th.e site of the ttcold" spot . 

Figure 51. 
Figure 52 . 
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Normal brain distribution of 75se-selenomethionine. 
99 75 Brain lesion visualized by "'Tc and Se dual isotope 
scan . Note lesion in different color (white) than normal 
brain tissue (blue) or normal accessory scalp structure 
(ye l l ow) . 
l,!gure 54 . 
Figure 53 . Myocardial scan with 75se-selenomethionine. 
75 131 Combination chest scan with Se -selenomethionine, I-
macro-aggregated serum albumin and al3lzSA. (a) Lungs in 
blue , myocardium in red and heart blood poo 1 in ·1hite. 
(b) Myocardium (blue). (c) Lungs, blood pool in the 
ventricles and top of the liver (red) . 
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Figure 54. 
b 
Combination chest scan with 7Sse-selenomethionine, 1311-
macro-aggregated serum albumin and Rl3l1sA. (a) Lungs in 
blue, myocardium in red and heart blood pool in i;,;hite. 
(b) Myocardium (blue). (c) Lungs, blood pool in the 
ventricles and top of the liver (red). 
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appear superior to the published scans using other isotopes (82 ,83). 
A specific application of this method is demonstrated in fig. 54. 
A patient whose chest x-ray showed an enlarged shadow of the heart was 
scanned to determine whether this shadow represents an enlarged heart or 
a pericardia! effusion. The patient was given 250 µci 75se-selenomethionine 
intravenously. One hour later 100 µci. 1311-iodinated serum albumin and 
1311-macroaggregated serum albumin ""ere administered intravenoudy to the 
patient. Ten minutes later the scan was performed. Fig. 54a shows the 
scan. 
The selenomethionine distribution is displayed in red, indicating that 
the entire interpulmonary space is occupied by the heart. The lungs are 
displayed in blue. The white and blue areas overlapping with red indicate 
the blood pools in the right and left ventricles. Fig. 54b shows the myo-
cardial scan, fig. 54c the lungs and the blood in the ventricles. 
III-c. Dosimetry. 
III-c-1. Total body irradiation. The dosimetric calculations of a 
radioactive material uniformly distributed in the body or a specific organ, 
may be carried out by the 0uimby-Marinelli formula (84). 
The dose due to /:;-radiation, DP: 
(A) D(::'. "" 73 .8 E CTe rads/µci - upon complete disintegration. 
The dose due to '6' -radiation, Df' : 
(B) D'f == o.~1346T'gCTe rads/µci - upon complete disintegration 
;;here: 
Et: • average 13-ray energy (Mev) 
C • concentration (µci/gm ) 
Te • effective half life (days) 
r - gamma ray constant (cm2 • rad) 
me • hr 
g • geometric factor (function of organ size) 
For a 70 kg normal male. the constants used in the above equations 
are as follows: 
i • 0.0105 Mev (7) 
Te • 46 days (III-a-1) 
c • _l_.1 ..... ic_i __ 
70,000 gm 
r • 2.0 cm2 - rad ( 7) 
me - hr 
g = 126 
Substituting these values in equation A and B. the result is: 
(A I) = 73.8 x 0.0105 x 46 
10.000 
= O.Smrad/µci 
(B') D(' • 0.0346 x 2.0 x 126 x 46 • 6.0mrad/µci 
70,000 
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For a tracer dose of 250 µci, the total body radiation dose from both 
f3 and rays is : 
(C) Dp+(" = 6.5 x 250 • 1,625mrads. 
1I1-c•2. Radiation dose to individual organs. As mentioned, equations 
A and B apply to individual organs as well as to the total body dose. The 
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constant used for the calculation of the dose for individual organs are 
shown in Table VI as well as the calculated doses. The total body dose of 
1.625 rads for 250 µci has to be added to each individual organ doae. 
The geometric factor g for each organ was calculated by the 
following method (84): 
The total mass (weight) of the organ is assumed to be shaped as a 
sphere. The radius R of this sphere is calculated. g is obtained by: 
g • 3 R.fi (RS lOcm) 
g • 4 R Ti (R > lOcm) 
The pancreas receives an additional radiation dose to that shown in 
Table VI, due to an initially high concentration of selenomethionine. 
It has been shown that 7% of the administered dose concentrate initially 
in the pancreas, before being secreted. These 7% have a half life of 24 
hours (10). This fraction would account for an additional 0.46 rads/250 
µci to the pancreas. 
Disregarding the radiation dose to the lung for reasons explained 
above (III·a-2). the organ that receives the highest radiation dose is the 
liver. 
The 72 hours tissue concentrations have been taken as initial con-
centrations for dosimetry purpose. In fig. 31 it is seen that by this 
time, the excretion ratio has stabilized and continues exponentially. 
CHAPTER IV. DISCUSSION 
IV~a. Half life studies. 
The biologic interpretation of the 3 phases observed int:he total 
body half life curves of normal subjects may be relevant to previously 
published data based on In Vitro studies (11.12,13,14). Phase A 
(TA • 9.5 hours) may be the elimination of unbound or nonpeptide bound 
75 1 Se-selenomethionine as well as relationship to the pancreatic-enter c 
recycling of 75se-selenomethionine. 
Phase B (TB • 8. 5 days) has an excretion rate of the same order of 
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magnitude as the half-time of serum protein and may represent incorpora• 
tion in the relatively rapid metabolizing protein pool, although no 
specific identification of an incorporating protein ha:> been accomplished. 
Phase C (Tc = 91 days) may represent incorporation in red cells, 
structural proteins and other stable protein moieties. From the data 
obtained by directional counting it would appear that incorporat!on into 
skeletal mu~cle proteins is a significant contribution to this p~ase. 
Thi& phase may also represent re-utilization of recycling 75se-seleno-
methionine (11 1 20). 
In the present study, the biological half life in man was dj.rectly 
measured for the first time. It is so far the only study of this type• 
The result - 73 days - is longer by a factor of 3 than the shortest 
estimated biological half life published (23,24) and shorter by a factor 
of 2 than the longest half life suggested (30). The previously published 
values were based on estimation from data obtained in animals. The present 
results prove once again, that such practice is inappropriate and should 
be avoided whenever possible. 
The biological half life in lymphoma patients has been shown to be 
significantly different from normal subjects quantitatively {slower) 
and qualitatively (2 phases compared to 3). 75se-selenomethionine has 
been shown to be an adequate index for protein synthesis and metabolism 
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by many authors (31·37). Therefore it would appear that the present data 
indicate a significant impairment of protein synthesis and metabolism in 
lymphoma patients. Although it "WOuld be premature to interpret the absence 
of phase B in lymphoma patients as an indication of altered serum protein 
synthesis and degradation, this fact should still be of considerable 
pathophysiological significance. It remains for future research on this 
subject to establish whether there actually is a connection between the 
75se•selenomethion1ne curves and protein metabolism in lymphoma patients 
and if so is it primary or secondary to the disease. As mentioned before, 
none of the patients in the group tested had any chemotherapy with anti-
metabolites throughout the duration of the experiment. 
In the case of severe diabetes, a very rapid excretion rate was 
measured. This fact may be attributed to the lack of insulin. It is well 
kno~m that amino acid incorporation into protein is impaired in diabetic 
patients (85,86,87). This result however, needs to he verified in an 
experiment where a statistically significant group of patients will be 
studied. The single case is not presented as a conclusive result, but 
rather as an observation indicating that further research may be of con-
siderable value. 
110 
The organ distribution studies in man presented here are based on 
a single case, and not on a normal subject, but a patient suffering from 
oronchogenic carcinoma. Still, this presents the best human data avail-
able to date. Animal studies were performed (10,15,17,18), but it 
~:ould appear that the distribution and concentration of selenomethionine 
in a normal man are more closely related to that observed in a sick man 
than to that observed in a normal animal. The most extensive results 
obtained from animal studies were published uy Anghileri and Marques (17). 
The only similarity hetween these results and the present information 
obtained from men, is that in both species the highest concentration is 
in the liver and kidneys and that the half life in skeletal muscle 
approaches infinity. 
The only organs with malignant involvements in the subject studied 
in the present work were the lungs and several metastatic lymph nodes. 
A large mediastinal tumor mass was found and fibrous infiltrations, 
necrosis and edema in the lungs. This accounts for the twice the normal 
weight of the lungs. The concentration in the tumor tissue and the 
malignant involved organs appeared to be of the same order - about 
0.35i/100 gr of tissue. 
The organs and tissues are arranged in Table VI in a descending 
order according to the 75se-selenomethionine concentration. Tbis order 
parallels roughly the order of protein synthetic metabolic activity of 
the organs. It therefore is possible that the concentration may serve 
as an index of metabolic activity. If we arbitrarily chose the relative 
r 
concentration index of 1.00 being equal to a concentration of 0.25%/100 
gr of tissue, the liver index would be 7.2 compared to an index of 0.16 
for bone. Whether this actually is the case remains to be established 
in future research. 
It is evident from the data, that the concentration in cardiac 
muscle is 4 times that of skeletal muscle of the legs. Although not 
proven this may be due to the higher rate of activity of the cardiac 
muscle, which functions rhythmically, and in an involuntary manner 
compared to the skeletal muscle. This may also account for the 2.5:1.0 
concentration found in the diaphragm compared to skeletal muscle. 
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The total body radiation dose of 1.625 rads per 250 µci administered 
intravenously is appreciable, but still within safe limits. This is 
approximately equal to the dose obtained from a gastrointestinal x .. ray 
series examination, which ia 1.4 roentgens (89). The organ doees too are 
of the same order as delivered by equivalent x-ray examinations. The 
kidney dose from kidney x-rays is 2 roentgens per exposure and from 
gallbladder radiography the dose is 2.5 roentgens per exposure to the liver 
(88). Compared to other radioisotope studies, the liver dose delivered by 
0.5 µci 60eo-cyanocobalamine for the Schilling test is 22.0 rads (89). 
The kidney dose from 150 µci 203Hg-chlonerodrin for kidney scanning is 
9.0 rads (89). The present results show doses of 5.3 rads to the liver 
and 3. 85 to the kidney from 250 uci 75se -se lenomethionine. These results 
indicate that a dose of 250 µci 75se-selenomethionine is a safe dose, 
well within the range of other established radiological and radioisotopical 
procedures. 
IV-b. Scannitl,i. 
Various investigators have reported on 75se-selenomethionine as 
a diagnostic agent in scanning the pancreas. Due to variable criteria 
of evaluation of scans anddtagnostic methodology, comparison between 
series is probably not very meaningful. Burke and Goldstein (90) made 
a correct diagnosis of carcinoma of the pancreas in 3 of 4 cases proven 
by surgery and diagnosed 2 cases of pancreatic insufficiency. Haynie 
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et al (91) evaluated 15 normal subjects, interpreting 12 as normal, l as 
abnormal and 2 as equivocal; 11 patients with carcinoma of the pancreas, 
interpreting one as normal, 7 as abnormal and 3 as equivocal; and 11 
patients with chronic pancreatitis, one as normal, 8 as abnormal and 
2 as equivocal. Sodee (92) made the correct diagnosis in 5 of 6 patients 
with carcinoma of the pancreas. Burdine and Haynie (93) reported scan 
interpretation in 29 patients with auspected pancreatic disease. Fourteen 
had normal scans; 10 patients had "focal areas" in the pancreas, of whom 
6 were found to have carcinoma of the pancreas by pathological examina-
tion, and the remaining 4 were not diagnosed. One patient was interpreted 
as having chronic pancreatitis and in 4 others liver interfered with the 
pancreatic scan. Brown et al evaluated 80 pancreatic scans of which 37 
were interpreted as normal, 39 as abnormal and 4 as technically unsatis-
factory. The normal scans included 33 normals, 2 pancreatitis and 1 tumor; 
the abnormal scans included 6 normals, 16 pancreatitis and 13 tumors. It 
mu~t be emphasized that in contrast to the above studies this investigation 
deals with diagnostic categorization into 4 classes: normal. carcinoma 
of the pancreas, pancreatic insufficiency and cirrhosis. The pancreatic 
T :i----------'"11 
113 
lesion must be of sufficient si~e to permit resolution by the colllma-
tion and the counting statistics of the scanning system e~ployed. 
Small lesions of less than 2 cm circumference would not be visualized 
by most scanning devices. The lesions reported by this technique are 
presumably examples of relatively massive replacement. Reference to 
lesion size includes secondary effect due to occlusion of pancreatic 
ducts. 
Diagnosis of pancreatic disease by 75se-selenomethionine scanning 
is atraumatic, the procedure can be tolerated by the most cachectic or 
gravely ill patient. The present data indicates that dual isotope scan 
may be helpful in diagnosing carcinoll\a of the pancreas. Particularly 
in cases of cancer in the body and tail, scanning may demonstrate 
suspicious areas which are not visualized by conventional barium meal 
examinations. 
Further investigation is indicated to more precisely determine the 
relationship of cirrhosis to the apparent decreased pancreatic uptake of 
75se-selenomethionine in this disease as compared to normals. The 
subtraction technique employed is not a significant factor in this 
observation as the decrease ts independent of liver-pancreas overlap. 
198 Colloidal Au uptake by the spleen may be a marker which will 
help to prevent erroneous diagnoses of carcinoma of the pancreas in 
patients with cirrhosis. 
When cirrho~is is not present (94), the opportunity to detect hepatic 
metastases by tne simultaneous hepatic scan is of clear advantage, giving 
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important information without the necessity of t~~ separate examinations. 
These data also indicate that the er.ergy-color modulation technique 
can support or suggest a diagnosi.s of chronic pancreatitis. The diffuse 
appearance of 75se-selenomethionine on these scans gives an appearance 
which was not seen in patients with carcinoma. 
Improvement of the method by tape recording ,the two channels of 
information as described above, permits great improvement of the quality 
of the image. This technique permits multiple image production at 
various channel ratios. Evaluation of pancreatic disease by this improved 
method has as yet not been completed. 
The myocardial scans produced by the tape recording technique are 
technically superior to any scans published, which have been done using 
other isotopes and conventional techniques. The mechanism of the rather 
selective uptake of 75se-selenomethionine by the myocardium is not well 
understood. A possible explanation has been offered in the discussion on 
the organ concentration studies. A clinical evaluation of this application 
of 75se•selenomethionine and the scanning techniques developed has as yet 
not been performed. 
Neither has the selenium-technetium brain scan been clinically 
evaluated. The advantage of this technique is obvious, as it permits 
discrimination between intracerebral and extracerebral lesions in the 
head, \.Jhich cannot be accomplished by use of 99nl.rechnet1um pertechne tate 
or any other scanning agent alone. 
SUMMARY 
(l) A scanning system has been developed which permits: 
(a) The subtraction of the radiation of one isotope from that 
of another. This permitted for the first time the 
visualization of the pancreas without the liver interference• 
improving this technique significantly. 
(b) Tlle display of the simultaneous distribution of two isotopes 
in different colors for each isotope. 
(c) Tape recording and color display of the scanning information. 
permitting ''rescanning" at optimal settings. 
(2) One hundred and nine pancreatic scans of the 220 patients scanned 
by this method were clinically evaluated. These scans were 
performed by the method described in (b) above. It was found 
that a high degree of accuracy in the diagnosis of pancreatic 
carcinoma was obtained. Th.ere are indications of a distinct 
pattern for the differential diagnosis of chronic pancreatitis and 
cirrhosis of the liver. 
(3) The use of 75se-selenomethionine and this system yields myocardial 
scans superior in quality compared t~ any other method to date. 
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(4) 75se-selenomethionine and 99'n.rc-pertechnetate used simultaneously 
for brain scanning permit the differentiation between intracerebral 
and extracerebral lesions observed by a technetium brain scan. 
(5) Three out of 5 hepatomas show ''positive" 75se-selenomethionine 
distribution in these tumors in scans done with colloid 198Au and 
75 Se-selenomethionine. 
(6) The biological half life of 75se-selenomethionine :f.n roan has been 
determined. It has been show11, in normal males, to be composed 
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of three phases: A• rapid, B- intermediate, C• slow. The combined 
biological half life was 73 days. 
(7) In patients with malignant lymphomas. the biological half life is 
composed of 2 phases only, phase B being absent and the combined 
biological half life being significantly shorter--45 days. It is 
proposed that this difference is due to impaired protein synthesis 
and metabolism in patients suffering from malignant lymphomas. 
(8) No significant difference was found between the biological half 
life of 75se-selenomethionine in pa.tients with chronic pancreatitis 
and normal subjects. 
(9) Tissue distribution and concentration studies have been carried out 
in a patient who expired 72 hours following the administration of 
250 µci 75se-selenomethionine. It is suggested that the concen-
tration pattern parallels that of protein i:;ynthesis metabolic acti• 
vity of the various tissues and organs. 
(10) Based on these results the total body radiation dose and that to 
individual organs, resulting from the intravenous administration 
of 250 µci to be of the same order as doses resulting from other 
presently employed radiological and radioisotopical diagnostic 
procedures. 
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